Amber Tomlinson
Adult Health · Albany, GANPI 1487198974
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 542 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 39 manufacturers, the largest accounting for just 10.4% — the pattern of someone who eats at a lot of different presentations. Among adult health clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 542 payments — averaging $17.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$1K
- Novo Nordisk$924
- AbbVie$824
- AstraZeneca$706
- GSK$671
- Bayer$607
- plus $5K from 33 others
What the payments were for
- Food & beverage$9,660100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,660 in reported general payments places this provider in the 95th percentile of 577 adult health providers in Georgia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 26 | $31,543 |
| EliquisApixaban | 33 | $29,134 |
| FarxigaDapagliflozin Propanediol | 15 | $18,682 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 26 | $17,968 |
| SynthroidLevothyroxine Sodium | 25 | $1,843 |
| Midodrine Hcl | 11 | $941 |
| Levothyroxine Sodium | 54 | $884 |
| Omeprazole | 60 | $830 |
| Atorvastatin Calcium | 62 | $758 |
| Losartan Potassium | 75 | $743 |
| Duloxetine Hcl | 16 | $703 |
| Gabapentin | 65 | $637 |
| Fluticasone Propionate | 30 | $592 |
| Metoprolol Succinate | 62 | $559 |
| Hydralazine Hcl | 31 | $473 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $924 | $31,54326 claims |
| PfizerEliquis | $1,008 | $29,13433 claims |
| AstraZenecaFarxiga | $706 | $18,68215 claims |
| GSKTrelegy Ellipta | $671 | $17,96826 claims |
| AbbVieSynthroid | $824 | $1,84325 claims |
| Almatica Pharma LLCSertraline Hcl | $62 | $37156 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 577 adult health providers in Georgia.
Other adult health in Albany
- Patricia KeeganAtlanta$224K
- Diane WirthAtlanta$132K
- Barbara WeberAtlanta$74K
- Terry HackworthAtlanta$49K
- Jenny DicksonCumming$39K
- Rachel NejemLawrenceville$31K
- Melissa BaughcumAthens$23K
- Kristine AdamsMarietta$21K
- Jenina LagascaAtlanta$17K
- Jennifer SheldonMacon$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.